MAPPING BENEFIT-RISK DECISION-MAKING PROCESSES AND IDENTIFYING DECISION POINTS WITH THE POTENTIAL TO INCLUDE PATIENT PREFERENCE INFORMATION THROUGHOUT THE MEDICAL PRODUCT LIFECYCLE
Author(s)
Whichello C1, Schölin Bywall K2, Mauer J3, Watt S4, Cleemput I5, Pinto CA6, van Overbeeke E7, Huys I8, de Bekker-Grob EW1, Hermann R9, Veldwijk J1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Uppsala University, Uppsala, Sweden, 3Pfizer, Collegeville, PA, USA, 4Pfizer, New York, NY, USA, 5Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium, 6Merck & Co., Inc., Kenilworth, NJ, USA, 7University of Leuven, Leuven, Belgium, 8KU Leuven, Leuven, Belgium, 9AstraZeneca, Wilmington, DE, USA
Conference/Value in Health Info
Value in Health, Vol. 21, S3 (October 2018)
Code
PMU100
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Multiple Diseases
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now